Dyax Corp. Announces Extension of Partnership with Bayer Corporation for Access to Dyax’s Fully-Human Antibody Phage Display Library

BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today, based on successful antibody discovery work during a research evaluation period, Bayer Pharma AG (Bayer) has executed a license to Dyax’s antibody phage display technology for development and potential commercialization of therapeutic antibody candidates identified using the Dyax library.

Back to news